Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-emptive VA111913 TS for Dysmenorrhoea (Randomised Double-Blind Cross-Over Study)
2009-012457-37Phase 2Completed
- Sponsor
- Vantia Therapeutics
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VA111913 in primary dysmenorrhea (PD) (2 arms), sponsored by Vantia Therapeutics. Primary endpoint: Time weighted sum of pain intensity (SPI) scores over 24 hours after onset of bleeding. Started Jul 2009; status: completed.
02
Drugs
VA111913
03
Conditions
primary dysmenorrhea (PD)
Beyond the preview
Go deeper on 2009-012457-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012457-37.